As part of our series focussing on research on new medicines in Australia, we have added a product review of the use of upadacitinib for moderately to severely active Crohn’s disease and ulcerative colitis.
This publication focuses on the efficacy and safety of upadacitinib and provides commentary from Associate Professor Jakob Begun, Director of IBD at the Mater Hospital in Brisbane and an Associate Professor at the School of Medicine, The University of Queensland.
Please login below to download this issue (PDF)